| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | 5.000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskab
> Arbejde med regulerende myndigheder | 1.000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | Neuromuskulær
> Duchenne | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 5.000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | Patientadvokatur
> Patientrettigheder | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 10.000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | Reumatisk
> Lupus | Regulatorisk partnerskab
> Deltag i Health Technology Assessment (HTA) og refusionsgennemgange | 100.000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Patientadvokatur
> Patientrettigheder | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | Blødning
> Blødningsforstyrrelser: de fleste typer | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 5.000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Ældre mennesker
> Ældre mennesker | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sjælden
> Sjældne sygdomme: metaboliske/lysosomale | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 100.000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | Reumatisk
> Reumatiske sygdomme: de fleste typer | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 10.000 | National | Regularly | 119062924366 |
| Ministry of Health. | Kardiovaskulær
> Hjerte-kar-sygdomme & hjertetilstande | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 5.000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 10.000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Regulatorisk partnerskab
> Deltag i/faciliter møder med politiske beslutningstagere/regulatorer | 1.000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | Kardiovaskulær
> Hjerte-kar-sygdomme & hjertetilstande | Regulatorisk partnerskab
> Med andre sundhedsforkæmpere | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | Gastrointestinal
> Gastrointestinal: andet | Regulatorisk partnerskab
> Med andre sundhedsforkæmpere | 1.000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | Sjælden
> Wilsons sygdom | Regulatorisk partnerskab
> Med andre sundhedsforkæmpere | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | Sjælden
> Sjældne sygdomme: genetisk | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 1.000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | Patientsikkerhed
> Iatrogen | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 1.000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 100.000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | Sjælden
> Sjældne sygdomme: genetisk | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | Lever
> Leversygdomme: transplantationer | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 5.000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | Respiratorisk
> Lungefibrose | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 1.000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | Sjælden
> Sjældne sygdomme: de fleste typer | Indflydelse på politik og lovgivning
> Påvirk sundhedspolitik og lovgivning | 100.000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | Blødning
> Blødningsforstyrrelser: de fleste typer | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 5.000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sygdomme generelt | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 100.000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | Neurologisk
> Multipel sklerose | Indflydelse på politik og lovgivning
> Deltag i offentlige høringer og konsultationer | 5.000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100.000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 5.000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | Sjælden
> Sjældne sygdomme: genetisk | Indflydelse på politik og lovgivning
> Mobiliser parlamentarikere og politiske ledere | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | Sjælden
> Sjældne sygdomme: genetisk | Indflydelse på politik og lovgivning
> Fortaler for lovforslag og rettigheder til beskyttelse af patienter | 1.000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | Gastrointestinal
> Cøliaki | Indflydelse på politik og lovgivning
> Bidrage til udarbejdelsen af folkesundhedslovgivning | 100.000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kræft
> Kræft: bugspytkirtel | Indflydelse på politik og lovgivning
> Håndtering af barrierer/anomalier i medicinsk behandling | 1.000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sjælden
> Sjældne sygdomme: genetisk | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | Respiratorisk
> KOL | Prisfastsættelse og overkommelighed
> Fortaler for retfærdig medicinprissætning | 1.000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sygdomme generelt | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | Sjælden
> Sjældne sygdomme: genetisk | Prisfastsættelse og overkommelighed
> Deltag i forhandlinger med prisrevisionsnævnet | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | Sjælden
> Sjældne sygdomme: metaboliske/lysosomale | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | Respiratorisk
> Luftveje: de fleste tilstande | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 5.000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | Respiratorisk
> KOL | Prisfastsættelse og overkommelighed
> Fortalelse af optagelse af produktet på refusionslister/nationale formularer | 1.000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | Kræft
> Kræft: bugspytkirtel | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 1.000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | Patientadvokatur
> Patientrettigheder | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | Endokrin
> Diabetes (både type 1 og type 2) | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 5.000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | Knogle
> Slidgigt og osteoporose | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 5.000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sygdomme generelt | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | Respiratorisk
> KOL | Forbedring af adgangsveje
> Fremme retfærdig adgang til medicin/sundhedspleje | 1.000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | Sjælden
> Sjældne sygdomme: de fleste typer | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 1.000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | 10.000 | National | Sometimes | 119073823192 |
| They consult us. | Neurologisk
> Fibromyalgi | Evidensbaseret patientinput
> Brug patientindsigt til at informere beslutninger | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | Sjælden
> Sjældne sygdomme: de fleste typer | Evidensbaseret patientinput
> Lever Real-World Evidence (RWE) til regulatoriske myndigheder | 1.000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | Sjælden
> Sjældne sygdomme: de fleste typer | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | 1.000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | Neurodegenerativ
> Alzheimers | Evidensbaseret patientinput
> Udnyt patienthistorier og fortællinger om levede erfaringer | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | Kronisk
> Kroniske sygdomme generelt | Evidensbaseret patientinput
> Omsæt evidens og indsigter til politisk input | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | Ældre mennesker
> Ældre mennesker | Diagnose og medicinlevering
> Sikr sikker og effektiv medicinbrug | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | Sjælden
> Von Hippel-Lindaus syndrom | Diagnose og medicinlevering
> Sikr sikker og effektiv medicinbrug | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Diagnose og medicinlevering
> Sikr sikker og effektiv medicinbrug | 10.000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | Ældre mennesker
> Ældre mennesker | Diagnose og medicinlevering
> Deltag i udvikling af kliniske retningslinjer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | Ældre mennesker
> Ældre mennesker | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | Blødning
> Hæmofili | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | Kardiovaskulær
> Hjerte-kar-sygdomme & hjertetilstande | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | Sjælden
> Sjældne sygdomme: de fleste typer | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 1.000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | Neurologisk
> Multipel sklerose | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 5.000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | Neurologisk
> Multipel sklerose | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 10.000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 10.000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 5.000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | Patientadvokatur
> Patientrettigheder | Institutionel styring
> Sikre repræsentation i statslige rådgivende organer | 10.000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | Neurologisk
> Neurologisk: de fleste tilstande | Institutionel styring
> Oprethold formel status som offentlig interesse- eller velgørenhedsenhed | 1.000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | Institutionel styring
> Oprethold formel status som offentlig interesse- eller velgørenhedsenhed | 5.000 | Local | Regularly | 119072832940 |
interaktioner
handlinger & fortalervirksomhed
19 omtaler
